𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The chemical synthesis and binding affinity to the EGF receptor of the EGF-like domain of heparin-binding EGF-like growth factor (HB-EGF)

✍ Scribed by Song Yub Shin; Tetsuo Yokoyama; Takato Takenouchi; Eisuke Munekata


Book ID
105360262
Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
125 KB
Volume
9
Category
Article
ISSN
1075-2617

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Heparin‐binding EGF‐like growth factor (HB‐EGF), which belongs to the EGF‐family of growth factors, was isolated from the conditioned medium of macrophage‐like cells. To investigate the effect of N‐ and C‐terminal residues of the EGF‐like domain of HB‐EGF in the binding affinity to the EGF receptor on A431 cell. We synthesized HB‐EGF(44–86) corresponding to the EGF‐like domain of HB‐EGF and its N‐ or C‐terminal truncated peptides. Thermolytic digestion demonstrated three disulfide bond pairings of the EGF‐like domain in HB‐EGF is consistent with that of human‐EGF and human‐TGF‐α. HB‐EGF(44–86) showed high binding affinity to EGF‐receptor, like human‐EGF. The truncation of the C‐terminal Leu^86^ residue from HB‐EGF(44–86), HB‐EGF(45–86) or HB‐EGF(46–86) caused a drastic reduction in the binding affinity to the EGF receptor. These results suggest that the EGF‐like domain of HB‐EGF plays an important role in the binding to the EGF receptor, and its C‐terminal Leu^86^ residue is necessary for binding with the EGF‐receptor. In addition, the deletion of the two N‐terminal residues (Asp^44^‐Pro^45^) from HB‐EGF(44–86) caused a 10‐fold decrease in relative binding affinity to the EGF receptor. This indicates that the two N‐terminal residues of the EGF‐like domain of HB‐EGF are necessary for its optimal binding affinity to the EGF receptor. Copyright © 2003 European Peptide Society and John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Induction of heparin-binding EGF-like gr
✍ Faye M. Johnson; Babita Saigal; Nicholas J. Donato 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 459 KB

Imatinib mesylate is a tyrosine kinase inhibitor of the ABL, platelet-derived growth factor receptor (PDGFR), and c-kit kinases. Inhibition of BCR-ABL and c-kit accounts for its clinical activity in leukemia and sarcoma, respectively. In this report, we describe other cellular targets for imatinib.

High expression of heparin-binding EGF-l
✍ Eiji Miyoshi; Shigeki Higashiyama; Takatoshi Nakagawa; Keiichiro Suzuki; Masayos 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 French ⚖ 511 KB

Heparin-binding epidermal growth factor (EGF)-like growth factor (HB-EGF) is a member of the EGF family and is highly expressed in hepatoma tissues but not in normal liver. However, it is unknown when HB-EGF is induced during hepatocarcinogenesis and what are the mechanisms underlying its high expre

Effects of epidermal growth factor (EGF)
✍ Dina Villanueva; Dana McCants; Heber C. Nielsen 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB 👁 2 views

Epidermal growth factor (EGF) causes gender-and development-specific changes in fetal lung surfactant synthesis. We hypothesized that the effects of EGF on development of surfactant synthesis are related to effects on EGF receptor (EGF-R) expression. We prepared sex-specific fetal rabbit lung organ